BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37174681)

  • 1. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
    Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease.
    Zheng P; Zheng X; Takehiro H; Cheng ZJ; Wang J; Xue M; Lin Q; Huang Z; Huang H; Liao C; Sun B
    J Transl Int Med; 2021 Sep; 9(3):212-222. PubMed ID: 34900632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease.
    Fotoh DS; Helal A; Rizk MS; Esaily HA
    Clin Rheumatol; 2021 Jul; 40(7):2689-2697. PubMed ID: 33474659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
    Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
    Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
    Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
    Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serum surfactant protein-D as a prognostic predictor in fibrotic hypersensitivity pneumonitis.
    Ejima M; Okamoto T; Suzuki T; Miyazaki Y
    Respir Investig; 2022 May; 60(3):369-378. PubMed ID: 34998715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
    Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
    BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
    Zhong D; Wu C; Bai J; Hu C; Xu D; Wang Q; Zeng X
    Medicine (Baltimore); 2020 Apr; 99(16):e19695. PubMed ID: 32311947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
    Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease.
    Avouac J; Cauvet A; Steelandt A; Shirai Y; Elhai M; Kuwana M; Distler O; Allanore Y
    PLoS One; 2020; 15(5):e0232978. PubMed ID: 32384128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Serum Biomarkers With Pulmonary Involvement of Rheumatoid Arthritis Interstitial Lung Disease: From KORAIL Cohort Baseline Data.
    Moon J; Lee JS; Yoon YI; Chang SH; Lee YA; Ha YJ; Kang EH; Park YB; Lee H; Choe JY; Lee EY;
    J Rheum Dis; 2021 Oct; 28(4):234-241. PubMed ID: 37476358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
    PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features.
    Xue M; Cai C; Zeng Y; Xu Y; Chen H; Hu H; Zhou L; Sun B
    Medicine (Baltimore); 2021 Jan; 100(4):e24260. PubMed ID: 33530214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.